Cladribine tablets as therapy for advanced relapsing-remitting multiple sclerosis: a 4-year follow-up real-world, multi-center, retrospective, cohort study.

ABSTRACT:

Introduction

Cladribine tablets (CladT) are a high-efficacy disease-modifying therapy recommended for the treatment of relapsing-remitting multiple sclerosis (RRMS) particularly in early disease. This study is aimed to evaluate the long-term efficacy of CladT in population of Polish RRMS patients, with more advanced disease.

Methods

This retrospective observational study included patients with RRMS who started CladT treatment between December 2019 and November 2023. Collected data included prior treatments, annualized relapse rate (ARR), magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS) score, no evidence of disease activity (NEDA-3), lymphocyte counts, and safety outcomes were collected.

Results

Of the 230 patients (8.3% treatment-naï

SUBMITTER: Pogoda-Wesolowska A 

PROVIDER: S-EPMC12272060 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature